Last reviewed · How we verify

traditional Covid -19 therapy

Beni-Suef University · Phase 2 active Small molecule Quality 0/100

traditional Covid -19 therapy is a Small molecule drug developed by Beni-Suef University. It is currently in Phase 2 development. Also known as: DExa /Corticosteriods.

At a glance

Generic nametraditional Covid -19 therapy
Also known asDExa /Corticosteriods
SponsorBeni-Suef University
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about traditional Covid -19 therapy

What is traditional Covid -19 therapy?

traditional Covid -19 therapy is a Small molecule drug developed by Beni-Suef University.

Who makes traditional Covid -19 therapy?

traditional Covid -19 therapy is developed by Beni-Suef University (see full Beni-Suef University pipeline at /company/beni-suef-university).

Is traditional Covid -19 therapy also known as anything else?

traditional Covid -19 therapy is also known as DExa /Corticosteriods.

What development phase is traditional Covid -19 therapy in?

traditional Covid -19 therapy is in Phase 2.

Related